)
Visual
test
Biomea Fusion
Biomea Fusion (BMEA) investor relations material
Biomea Fusion Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary24 Mar, 2026
Executive summary
Advanced from preclinical validation to generating durable clinical data in type 2 diabetes with icovamenib, showing persistent 52-week clinical activity after a 12-week treatment course.
Initiated two Phase II trials (COVALENT-211 and COVALENT-212) for icovamenib in type 2 diabetes, with 26-week primary endpoint data expected in Q4 2026.
Launched Phase I trial for BMF-650 (GLP-131) in obesity, with initial 28-day weight reduction data anticipated in Q2 2026.
Completed 52-week follow-up from Phase II COVALENT-112 (icovamenib in type 1 diabetes), with data expected in Q2 2026.
Projected cash runway extends into Q1 2027.
Financial highlights
Cash, cash equivalents, and restricted cash totaled $56.2 million as of December 31, 2025, down from $58.6 million at year-end 2024.
Net loss attributable to common stockholders was $61.8 million for 2025, compared to $138.4 million in 2024.
Research and development expenses were $62.0 million in 2025, down from $118.1 million in 2024, reflecting strategic realignment and reduced headcount.
General and administrative expenses were $19.3 million in 2025, down from $26.0 million in 2024.
Stock-based compensation totaled $9.5 million in 2025, down from $19.1 million in 2024.
Outlook and guidance
Anticipates 26-week primary endpoint data from two Phase II icovamenib studies in type 2 diabetes in Q4 2026.
Expects 52-week follow-up data from Phase II COVALENT-112 (type 1 diabetes) in Q2 2026.
Initial 28-day weight reduction data from Phase I GLP-131 (BMF-650 in obesity) expected in Q2 2026.
Cash runway projected into Q1 2027.
Distinguish COVALENT-211 and 212 T2D populations
Drivers of the $56M R&D expense reduction
Clinical evidence for beta cell restoration
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biomea Fusion
- Novel diabetes and obesity therapies show durable efficacy, with pivotal data expected in 2024.BMEA
The Citizens Life Sciences Conference 202610 Mar 2026 - Oral therapies show durable diabetes control and robust preclinical weight loss, with pivotal data ahead.BMEACorporate presentation27 Feb 2026
- Icovamenib and BMF-650 progress in trials, targeting diabetes and obesity with novel mechanisms.BMEAOppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026
- Durable A1C reduction and weight loss assets advance, with pivotal data and strong cash runway ahead.BMEA44th Annual J.P. Morgan Healthcare Conference3 Feb 2026
- FDA lifts clinical hold on BMF-219 diabetes trials; key data readouts expected by year-end 2024.BMEAFDA Announcement20 Jan 2026
- Icovamenib boosts GLP-1 therapy efficacy; BMF-650 shows strong oral potential for diabetes.BMEAStatus Update17 Jan 2026
- Icovamenib and BMF-650 offer durable, disease-modifying oral therapies for diabetes and obesity.BMEACorporate presentation14 Jan 2026
- Phase 2 diabetes data will soon define optimal Menin inhibitor use and guide late-stage plans.BMEAPiper Sandler 36th Annual Healthcare Conference12 Jan 2026
- Major diabetes trial readout expected by year-end to define optimal patients and dosing.BMEA7th Annual Evercore ISI HealthCONx Healthcare Conference11 Jan 2026
Next Biomea Fusion earnings date
Q1 20264 May, 2026
Biomea Fusion
Next Biomea Fusion earnings date
Q1 20264 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage